Literature DB >> 16765672

Prospective controlled study of vapor pressure tear osmolality and tear meniscus height in nasolacrimal duct obstruction.

Ulrike Stahl1, Ian C Francis, Fiona Stapleton.   

Abstract

PURPOSE: To determine tear osmolality (TO) and tear meniscus height (TMH) in patients with functional (FNLDO) and primary acquired (PANDO) nasolacrimal duct obstruction. Additionally, to determine the effect of successful dacryocystorhinostomy surgery on these tear parameters.
DESIGN: Prospective case-controlled interventional case series.
METHODS: Up to 20 microl of basal tears were collected from 20 age- and gender-matched control subjects, 33 patients with FNLDO, 28 patients with PANDO, and 31 patients after successful dacryocystorhinostomy. TMH was measured with videoreflective dacryomeniscometry, and TO was measured with vapor pressure osmometry.
RESULTS: Thirty-nine percent of the patients with FNLDO (13/33) elected to undergo dacryocystorhinostomy surgery, compared with 64% of the patients with PANDO (18/28; P = .09). TMH was significantly higher in the disease groups (FNLDO median, 630 +/- 187 microm; PANDO median, 620 +/- 210 microm) compared with the control subjects (median 262 +/- 50 microm; P < .01). In those patients who underwent surgery, TMH was slightly higher in FNLDO than PANDO (P = .08), and TMH reduced significantly after surgery (P < .05). Mean TO in the control subjects was 313 +/- 17 mmol/kg, in FNLDO was 309 +/- 19 mmol/kg, and in PANDO was 315 +/- 24 mmol/kg (P > .05). TO was similar in those patients who progressed to surgery compared with the total group and was unaffected by surgery.
CONCLUSION: TO was similar in normal control subjects and in the watery eye group and was unchanged after dacryocystorhinostomy surgery. Despite the slightly higher TMH in patients with FNLDO, a higher proportion of patients PANDO elected to have surgery. Relative to FNLDO, patients with PANDO who progressed to surgery had lower TMH and normal TO, which suggests that a complete lacrimal drainage obstruction induces negative feedback that results in no reduction in TO.

Entities:  

Mesh:

Year:  2006        PMID: 16765672     DOI: 10.1016/j.ajo.2005.12.051

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  7 in total

1.  Effect of topical steroids on recently developed incomplete nasolacrimal duct obstruction: optical coherence tomography study.

Authors:  Min Kyu Yang; Namju Kim; Ho-Kyung Choung; Sang In Khwarg
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-07-24       Impact factor: 3.117

2.  Reduced tear break-up time in the fellow eye of patients with unilateral primary acquired nasolacrimal duct obstruction.

Authors:  Nesime Setge Tıskaoğlu; Alper Yazıcı
Journal:  Int Ophthalmol       Date:  2022-09-02       Impact factor: 2.029

3.  Daytime variations of tear osmolarity and tear meniscus volume.

Authors:  Ming Li; Chixin Du; Dexi Zhu; Meixiao Shen; Lele Cui; Jianhua Wang
Journal:  Eye Contact Lens       Date:  2012-09       Impact factor: 2.018

4.  Symptom assessment in patients with functional and primary acquired nasolacrimal duct obstruction before and after successful dacryocystorhinostomy surgery: a prospective study.

Authors:  L M Cheung; I C Francis; F Stapleton; G Wilcsek
Journal:  Br J Ophthalmol       Date:  2007-06-21       Impact factor: 4.638

5.  Analysis of basal and reflex human tear osmolarity in normal subjects: assessment of tear osmolarity.

Authors:  Ali A Abusharha; Tariq M AlShehri; Abdullah Y Hakami; Ali M Alsaqr; Raied A Fagehi; Saud A Alanazi; Ali M Masmali
Journal:  Ther Adv Ophthalmol       Date:  2018-08-21

Review 6.  Tear film osmolarity and dry eye disease: a review of the literature.

Authors:  Richard Potvin; Sarah Makari; Christopher J Rapuano
Journal:  Clin Ophthalmol       Date:  2015-11-02

7.  Spectral domain optical coherence tomography for measuring tear film meniscus height and its relationship with epiphora.

Authors:  Swati Singh; Anu Rajput; Ashik Mohamed; Vikas Mittal
Journal:  Indian J Ophthalmol       Date:  2018-11       Impact factor: 1.848

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.